Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cytosolic epoxide hydrolase in humans: development and tissue distribution.

Literature DB >> 3240091

Cytosolic epoxide hydrolase in humans: development and tissue distribution.

G M Pacifici¹, A Temellini, L Giuliani, A Rane, H Thomas, F Oesch.

Abstract

Cytosolic epoxide hydrolase activity was measured towards trans-stilbene oxide in 41 human adult livers, in 40 fetal livers, in 17 placentas and in fetal and adult lungs, kidneys and gut. The cytosolic epoxide hydrolase activity was measurable in all specimens investigated. The rate of formation of trans-stilbene glycol (pmol/min per mg protein, mean +/- SD) was 55.2 +/- 89.6 (fetal liver). 303.2 +/- 73.2 (adult liver) and 18.8 +/- 13.1 (placenta) In the fetal extrahepatic tissues, the cytosolic epoxide hydrolase activity was 70.0 +/- 9.4 (adrenals), 47.6 +/- 7.2 (gut), 69.4 +/- 22.5 (kidneys) and 43.2 +/- 19.2 (lungs) pmol/min per mg protein, whereas in the adult tissues it was 131.2 +/- 63.1 (kidneys), 27.8 +/- 20.3 (intestine), 8.5 +/- 2.8 (lungs) and 7.2 +/- 4.2 (urinary bladder) pmol/min per mg protein.

Entities: Chemical Species

Mesh：

Substances：
Epoxide Hydrolases

Year: 1988 PMID： 3240091 DOI： 10.1007/bf00332483

Source DB: PubMed Journal: Arch Toxicol ISSN： 0340-5761 Impact factor: 5.153

21 in total

1. Arene oxides and the NIH shift: the metabolism, toxicity and carcinogenicity of aromatic compounds.

Authors: J W Daly; D M Jerina; B Witkop
Journal: Experientia Date: 1972-10-15

2. Arene oxides: a new aspect of drug metabolism.

Authors: D M Jerina; J W Daly
Journal: Science Date: 1974-08-16 Impact factor: 47.728

3. Concomitant induction of cytosolic but not microsomal epoxide hydrolase with peroxisomal beta-oxidation by various hypolipidemic compounds.

Authors: L Schladt; R Hartmann; C Timms; M Strolin-Benedetti; P Dostert; W Wörner; F Oesch
Journal: Biochem Pharmacol Date: 1987-02-01 Impact factor: 5.858

4. Formation of a 16,17-trans-glycolic metabolite from a 16-dehydro-androgen in human fetal liver microsomes.

Authors: A Rane; J A Gustafsson
Journal: Clin Pharmacol Ther Date: 1973 Sep-Oct Impact factor: 6.875

5. Cytosolic and microsomal epoxide hydrolases: differential properties in mammalian liver.

Authors: K Ota; B D Hammock
Journal: Science Date: 1980-03-28 Impact factor: 47.728

6. Distribution and properties of a mammalian soluble epoxide hydrase.

Authors: S S Gill; B D Hammock
Journal: Biochem Pharmacol Date: 1980-02 Impact factor: 5.858

7. Metabolism of styrene oxide in different human fetal tissues.

Authors: G M Pacifici; A Rane
Journal: Drug Metab Dispos Date: 1982 Jul-Aug Impact factor: 3.922

8. Interindividual variations in the activities of cytosolic and microsomal epoxide hydrolase in human liver.

Authors: I Mertes; R Fleischmann; H R Glatt; F Oesch
Journal: Carcinogenesis Date: 1985-02 Impact factor: 4.944

9. Glutathione S-transferase in humans: development and tissue distribution.

Authors: G M Pacifici; M Franchi; C Colizzi; L Giuliani; A Rane
Journal: Arch Toxicol Date: 1988 Impact factor: 5.153

10. Cytosolic and microsomal epoxide hydrolases are immunologically distinguishable from each other in the rat and mouse.

Authors: T M Guenthner; B D Hammock; U Vogel; F Oesch
Journal: J Biol Chem Date: 1981-04-10 Impact factor: 5.157

15 in total

Review 1. Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

Authors: Hong C Shen; Bruce D Hammock
Journal: J Med Chem Date: 2012-01-17 Impact factor: 7.446

Cytosolic epoxide hydrolase in humans: development and tissue distribution.

1. Arene oxides and the NIH shift: the metabolism, toxicity and carcinogenicity of aromatic compounds.

2. Arene oxides: a new aspect of drug metabolism.

3. Concomitant induction of cytosolic but not microsomal epoxide hydrolase with peroxisomal beta-oxidation by various hypolipidemic compounds.

4. Formation of a 16,17-trans-glycolic metabolite from a 16-dehydro-androgen in human fetal liver microsomes.

5. Cytosolic and microsomal epoxide hydrolases: differential properties in mammalian liver.

6. Distribution and properties of a mammalian soluble epoxide hydrase.

7. Metabolism of styrene oxide in different human fetal tissues.

8. Interindividual variations in the activities of cytosolic and microsomal epoxide hydrolase in human liver.

9. Glutathione S-transferase in humans: development and tissue distribution.

10. Cytosolic and microsomal epoxide hydrolases are immunologically distinguishable from each other in the rat and mouse.

Review 1. Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

2. Development of a high throughput cell-based assay for soluble epoxide hydrolase using BacMam technology.

3. In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s.

4. Conjugation pathways in liver disease.

5. Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms.

6. Upregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage.

Review 7. Extrahepatic metabolism of drugs in humans.

8. Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2.

9. Expression and regulation of soluble epoxide hydrolase in adipose tissue.

10. Valpromide is a poor inhibitor of the cytosolic epoxide hydrolase.